Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Mylan says appeals ruling allows May 2014 launch of generic Copaxone
Mylan (MYL) announced the U.S. Court of Appeals for the Federal Circuit has reversed a district court's finding related to Teva's (TEVA) U.S. Patent 5,800,808 for Copaxone, thereby invalidating the patent. Mylan CEO Heather Bresch said, "We are very pleased with today's ruling and we expect that it will allow Mylan to launch its generic version of Copaxone on May 25, 2014 upon expiration of Teva's Orange Book patents, subject to Mylan's final regulatory approval." All other rulings by the district court have been affirmed, according to Mylan.